Business
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Oct. 2, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Oct. 2, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to treat life-threatening medical and surgical conditions around the world, announces positive surgical outcomes in a recent publication entitled, \"CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding,\" in the journal Annals of Thoracic Surgery, ahead of the European Association of Cardio-thoracic Surgery Annual Meeting in Lisbon, Portugal, October 3-5, 2019.\n\n \nIn this recent retrospective study, Dr. Kambiz Hassan, MD, and colleagues at Asklepios Klinik St. Georg in Hamburg, Germany reported on the clinical outcomes of the investigational application of CytoSorb in patients at their institution who underwent emergency cardiac surgery (primarily coronary artery bypass graft surgery) on either ticagrelor or rivaroxaban two commonly prescribed antithrombotic agents. Specific outcomes included the need for blood transfusions, unwanted bleeding events, surgical drainage, and the need for rethoracotomy (i.e. re-opening the chest cavity to explore the source of blood loss). The study evaluated 55 consecutive patients who underwent emergency cardiac surgery between June 2016 and June 2018 while on anti-thrombotic therapy (43 on ticagrelor, 12 on rivaroxaban). Of these, CytoSorb was incorporated into cardiopulmonary bypass in 32 patients on ticagrelor, and 7 on rivaroxaban. Bleeding complications during and after surgery were analyzed in both the CytoSorb adsorption and the Control (no CytoSorb) groups (nominal p-values were computed for clinical outcomes, unadjusted for multiplicity). \nIn the CytoSorb adsorption group, none of the 39 patients underwent rethoracotomy, whereas 6 of 16 patients in the Control group required rethoracotomy (0.0% vs 37.5% control, p=0.0003). 24-hour median drainage volumes in the CytoSorb group was significantly lower than the Control group (p=0.0037) in patients receiving ticagrelor (350 mL vs 890 mL Control) and rivaroxaban (390 mL vs 600 mL Control). Compared with the CytoSorb treated group, the Control group had multiple bleeding complications. In general, transfusion of blood products was not necessary for the majority of CytoSorb treated patients, with 31/39 (79.5%) not requiring packed red blood cell tran...